Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study

Table 3 Incidence rates, IR (per 1 person-year), incidence rates ratios, IRR, of risk of treatment modification due to different types of toxicities

Incidence rates and incidence rate ratios for changes in HAART during the first year due to the following reasons:	Women IR 95%(CI)	Men IR 95%(CI)	Women vs. men (ref) unadjusted IRR 95%(CI)	Women vs. men (ref) adjusted IRR 95%(CI)
Toxicity, hypersensitivity	0.09 (0.06-0.15)	0.06 (0.03-0.14)	1.43 (0.58-3.52)	−¹
Toxicity, gastrointestinal	0.22 (0.16-0.15)	0.16 (0.10-0.26)	1.37 (0.80-2.36)	0.97 (0.49-1.93)
Toxicity, neurological	0.19 (0.13-0.27)	0.20 (0.13-0.30)	0.96 (0.56-1.64)	1.48 (0.65-3.38)
Toxicity, other	0.18 (0.13-0.25)	0.29 (0.21-0.40)	0.62 (0.39-1.00)	−¹

¹ No estimate available, due to shortage of events.
Poisson regression analyses of incidence rates, IR (95% CI), and incidence rates ratios, IRR (95% CI), adjusted by time-updated age, race, time-updated CD4 count, time-updated viral load, prior or current AIDS at HAART initiation, body weight and initiation period (< January 1st 2003 and >= January 1st 2003).

ISSN: 1471-2334